Trevena announces acceptance of abstract examining use of OLINVYK

Trevena announced the acceptance of an abstract based on the pRospective, case-controlled Evaluation of oLIceridine for moderate or sEVEre pain in patients with acute burn injuries, RELIEVE, study at the 2024 ABA annual meeting, being held April 9th-12th in Chicago. The study was conducted as an investigator-initiated trial and was led by David Hill, PharmD. from the Firefighters Burn Center in Memphis, TN. Dr. Hill was independently responsible for the development and submission of the abstract. The single-center, prospective, case-controlled study was dual IRB approved and included 10 patients with burn injuries admitted between April and September 2023 and treated with OLINVYK. Dosing and assessments were followed per study protocol and safety and efficacy assessed by study team daily at a minimum. Patients dosed with OLINVYK were compared to a matched historical control group which included treatment across a range of other IV opioids. “The results of the RELIEVE study will be reported during the ABA meeting and we are pleased to see additional clinical data in this patient type where new therapeutic options are needed,” stated Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena. “We look forward to the presentation of these data in the spring.”